


 $+$:

Substitute for form 1449A/PTO <div style="text-align: center; font-weight: bold; font-size: 1.2em;"> INFORMATION DISCLOSURE STATEMENT BY APPLICANT </div> <div style="text-align: center; margin-top: 10px;">  <p>(use as many sheets as necessary)</p> </div>	<div style="text-align: center; font-weight: bold; margin-bottom: 10px;"> Complete if Known </div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;">Application Number</td> <td style="width: 50%; padding: 5px;">09/269,903</td> </tr> <tr> <td style="padding: 5px;">Filing Date</td> <td style="padding: 5px;">May 6, 1999</td> </tr> <tr> <td style="padding: 5px;">First Named Inventor</td> <td style="padding: 5px;">Peter James Watts</td> </tr> <tr> <td style="padding: 5px;">Group Art Unit</td> <td style="padding: 5px;">1645 1616</td> </tr> <tr> <td style="padding: 5px;">Examiner Name</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Attorney Docket Number</td> <td style="padding: 5px;">WC 131</td> </tr> </table>	Application Number	09/269,903	Filing Date	May 6, 1999	First Named Inventor	Peter James Watts	Group Art Unit	1645 1616	Examiner Name		Attorney Docket Number	WC 131
Application Number	09/269,903												
Filing Date	May 6, 1999												
First Named Inventor	Peter James Watts												
Group Art Unit	1645 1616												
Examiner Name													
Attorney Docket Number	WC 131												

[illegible]

Examine Signature	<i>Frank Cho</i>	Date Considered	2/22/01
----------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/269,903
Filing Date	May 6, 1999
First Named Inventor	Peter James Watts
Group Art Unit	1815 1616
Examiner Name	
Attorney Docket Number	WC 131

Sheet	2	of	4
-------	---	----	---

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
JL		DE	42 36 025	A1	Merck Patent GmbH	04-28-1994		
		GB	2 166 051	A	Alza Corp.	04-30-1986		
		GB	2 174 599	A	Norwich Eaton Pharmaceuticals Inc.	11-12-1986		
		GB	2 238 243	A	National Research Development Corp.	05-29-1991		
		EP	0 221 601	A1	Janssen Pharmaceutica N.V.	05-13-1987		
		EP	0 338 383	A2	Schwarz Pharma AG	10-25-1989		
		EP	0 365 947	A1	Pharmacia AB	05-02-1990		
		EP	0 513 035	B1	Danbiosyst UK Ltd.	10-20-1993		
		EP	0 519 870	A1	Spirig AG Pharmazeutische Präparate	12-23-1992		
		EP	0 572 942	A2	Poli Industria Chimica S.p.A.	12-08-1993		
		EP	0 621 032	A1	Ciba-Geigy AG	10-26-1994		
		EP	0 640 337	A2	SS Pharmaceutical Co. Ltd.	03-01-1995		
		EP	0 673 645	A2	F. Hoffmann-La Roche AG	09-27-1995		
		WO	89/11269	A1	Agricultural and Food Research Council	11-30-1989		
		WO	90/13286	A1	Chugai Seiyaku Kabushiki Kaisha	11-15-1990		
		WO	91/16881	A1	Development Company of the Hebrew University of Jerusalem	11-14-1991		
JL		WO	92/01457	A1	Rhodes, et al.	02-06-1992		
		WO	92/14452	A1	Rhodes, et al.	09-03-1992		
		WO	95/06464	A1	Galenik Labor Freiburg GMBH	03-09-1995		
		WO	95/14037	A1	Ibah, Inc.	05-26-1995		
		WO	95/35100	A1	Danbiosyst UK Ltd.	12-28-1995		
		WO	96/30016	A2	Janssen Pharmaceutica N.V.	10-03-1996		

Examine Signature	<i>Shankh Chai</i>	Date Considered	2/22/01
----------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.


Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/269,903
		Filing Date	May 6, 1999
		First Named Inventor	Peter James Watts
		Group Art Unit	1615 / 6/6
		Examiner Name	
Sheet 3 of 4	Attorney Docket Number	WC 131	



OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
JL		ASHFORD, et al., "In Vivo Assessment of Colonic Drug Delivery Systems," <i>Br. Pharm. Conference Abstract</i> 13, p. 1049 (1992).	
		BURNS, et al., "An in vitro assessment of liquid-filled Capill [®] potato starch capsules with biphasic release characteristics," <i>Int. J. Pharm.</i> 134:223-30 (1996).	
		HEALEY, "Enteric Coatings and Delayed Release" in <i>Drug Delivery to the Gastrointestinal Tract</i> (Hardy, et al., eds.) Ellis Horwood:Chichester, 1989.	
		KENYON, et al., "The effect of food on the in vivo behaviour of enteric coated starch capsules," <i>Int. J. Pharm.</i> 112:207-13 (1994).	
		KOPE EK, et al., "Polymers for colon-specific drug delivery," <i>J. Control. Rel.</i> 19:121-30 (1992).	
		MILOJEVIC, et al., "In Vitro and In Vivo evaluation of amylose coated pellets for colon specific drug delivery," <i>Proceed. Intern. Symp. Control. Rel. Bioact. Mater.</i> 20:288-89 (1993).	
		RUBINSTEIN & GLIKO-KABIR "Synthesis and swelling-dependent enzymatic degradation of borax-modified guar gum for colonic delivery purposes," <i>S.T.P. Pharma Sciences</i> 5:41-46 (1995).	
		RUBINSTEIN, et al., "Colonic Drug Delivery: Enhanced Release of Indomethacin from Cross-Linked Chondroitin Matrix in Rat Cecal Content," <i>Pharm. Res.</i> 9(2):276-78 (1992).	
		RUBINSTEIN, et al., "In Vitro Evaluation of Calcium Pectinate: A Potential Colon-Specific Drug Delivery Carrier," <i>Pharm. Res.</i> 10(2):258-63 (1993).	
OR		SIEFKE, et al., "Colon Targeting with β -CD Matrix Films," <i>Eur. J. Pharm. Biopharm.</i> 40 (suppl.):33S (1994).	

Examiner's Signature	<i>Shankha Chandra</i>	Date Considered	2/24/01
----------------------	------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/269,903
		Filing Date	May 6, 1999
		First Named Inventor	Peter James Watts
		Group Art Unit	4645 1010
		Examiner Name	
Sheet 4 of 4	Attorney Docket Number	WC 131	

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
JL		THE UNITED STATES PHARMACOPOEIA, USP23, pp. 1791-93 (1994).	
		VAN DEN MOOTER, "Azo polymers for colon-specific drug delivery," <i>Int. J. Pharm.</i> 87:37-46 (1992).	
JL		WILDING, et al., "Gastrointestinal Transit and Systemic Absorption of Captopril from a Pulsed-Release Formulation," <i>Pharm. Res.</i> 9(5):654-57 (1992).	

Examiner's Signature	<i>Frank Cho</i>	Date Considered	2/28/01
----------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+